Ratings by Craig-Hallum (Albert Lowe)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | Cardiff Oncology | CRDF | Downgrade | Hold (Buy) |
1.51 (0.88) |
-41.72% | Details | |
| 5/15/2026 | Neurogene | NGNE | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2026 | Cardiff Oncology | CRDF | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2026 | SAB Biotherapeutics | SABS | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2026 | Rezolute | RZLT | Maintain | Hold (N/A) |
|
Details | ||
| 2/12/2026 | Atossa Genetics | ATOS | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Atossa Genetics | ATOS | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2025 | Rezolute | RZLT | Downgrade | Hold (Buy) |
10.94 (4.61) |
-57.86% | Details | |
| 12/4/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
91.91 (157.24) |
71.08% | Details | |
| 11/14/2025 | Actuate Therapeutics | ACTU | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 10/6/2025 | Skye Bioscience | SKYE | Downgrade | Hold (Buy) |
4.75 (0.65) |
-86.32% | Details | |
| 10/2/2025 | Eupraxia Pharmaceuticals | EPRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/25/2025 | Echelon | ELON | New Coverage | Buy (N/A) |
11.97 (21.88) |
82.79% | Details | |
| 6/17/2025 | Neurogene | NGNE | New Coverage | Buy (N/A) |
18.97 (37.31) |
96.68% | Details | |
| 6/5/2025 | Atossa Genetics | ATOS | New Coverage | Buy (N/A) |
0.86 (2.49) |
189.53% | Details | |
| 6/2/2025 | Actuate Therapeutics | ACTU | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2025 | Actuate Therapeutics | ACTU | New Coverage | Buy (N/A) |
8.37 (1.44) |
-82.8% | Details | |
| 4/1/2025 | SAB Biotherapeutics | SABS | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2025 | Skye Bioscience | SKYE | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2025 | Lineage Cell Therapeutics Inc. | LCTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/21/2025 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Buy (N/A) |
3.55 (6.59) |
85.63% | Details | |
| 10/9/2024 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
2.67 (3.54) |
32.58% | Details | |
| 9/6/2024 | Cardiff Oncology | CRDF | New Coverage | Buy (N/A) |
2.21 (1.51) |
-31.67% | Details | |
| 8/26/2024 | Skye Bioscience | SKYE | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2024 | Lineage Cell Therapeutics Inc. | LCTX | New Coverage | Buy (N/A) |
0.88 (1.16) |
31.82% | Details | |
| 7/9/2024 | Skye Bioscience | SKYE | New Coverage | Buy (N/A) |
6.15 (4.75) |
-22.76% | Details | |
| 5/13/2024 | PMV Pharmaceuticals Inc. | PMVP | New Coverage | Buy (N/A) |
2.04 (1.34) |
-34.31% | Details |
